New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
Tóm tắt
Từ khóa
Tài liệu tham khảo
Monnier, C (2002). Les plantes Medicinales. Vertus et Traditions, Privat Eds. Toulouse.
Sweldlow, J (2000). Nature and Medicine, National Geographic Mil Eds.
Ellis, R (2001). Aquagenesis. The origin and evolution of life in the sea, Viking Eds.
Macdougall, J.D. (1996). A short history of Planet Earth, John Wiley Eds.
Argulis, L., and Schwartz, K (1982). Five Kingdoms, an illustrated guide to the phyla of life on Earth, W.H. Freeman & Company.
Scotfield, 1982, Protocordate allorecognition is controlled by aq MHC-like gene, Nature, 295, 499, 10.1038/295499a0
Pendergast, 1983, Direct inflammation: the phylogeny of lymphokines, Dev. Comp. Inmunol, 7, 629, 10.1016/0145-305X(83)90080-0
Haefner, 2003, Drugs from the deep. Marine natural products as drug candidates, Drug Discov Today, 8, 536, 10.1016/S1359-6446(03)02713-2
Longley, 1991, Discodermolide - A new marine derived Inmunosuppressive compound, Transplantation, 52, 650, 10.1097/00007890-199110000-00014
Angerhofer, 1992, Antimalarial activity of Sestiperquenes from the marine sponge Acanthella klelthra, J. Nat. Prod, 55, 1787, 10.1021/np50090a014
Nagai, 1992, Gambieric acids, New potent antifungal substances with unprecedent polyether structures from a marine dinoflagelate Gambiercus toxicus, J. Org. Chem, 57, 5448, 10.1021/jo00046a029
Alonso, 2003, Drugs from the Sea: Conotoxins as Drug Leads for Neuropathic Pain and Other Neurological Conditions, Min. Rev. Med. Chem, 3, 785, 10.2174/1389557033487746
Craigg, 1997, Coral reefs, forests and thermal vents: The worldwide exploration of nature for novel antitumor agents, Semin. Oncol, 24, 156
Bergmann, 1985, Contributions to the study of marine products. The nucleosides of sponges III. Spongothymidine and Spongouridine, J. Org. Chem, 20, 1501, 10.1021/jo01128a007
Wolf, 1985, High dose cytosine arabinoside and daunorubicin as consolidation therapy for acute non lymphoblastic leukemia, Blood, 65, 1407, 10.1182/blood.V65.6.1407.bloodjournal6561407
Moore, 1996, Activity of gemcitabine in patients with advanced pancreatic carcinoma: a review, Cancer, 78, 633, 10.1002/(SICI)1097-0142(19960801)78:3+<633::AID-CNCR8>3.0.CO;2-B
Guchelaar, 1996, Clinical, toxicological and pharmacological aspects of gemcitabine, Cancer. Treat. Rep, 22, 15, 10.1016/S0305-7372(96)90014-6
Mayer, 2003, Marine pharmacology in 2000: antitumor and cytotoxic compounds, Int J Cancer, 105, 291, 10.1002/ijc.11080
Amador, 2003, Progress in the development and acquisition of anticancer agents from marine sources, Ann Oncol, 14, 1607, 10.1093/annonc/mdg443
Rinehart, 1990, Ecteinascidins 729, 743, 745, 759ª, 759b and 770. Potent antitumor compounds from the Caribbean tunicate Ecteinascidia Turbinata, J Org Chem, 55, 4515, 10.1021/jo00302a007
Jimeno, 1996, Progress in the acquisition of new marine derived anticancer compounds: development of ecteinascidin-743 (ET-743), Drugs of the Future, 21, 1155, 10.1358/dof.1996.021.11.385487
Minuzzo, 2000, Interference of transcriptional activation by the anti-neoplastic drug ET-743, Proc.Natl.Acad.Sci.USA, 97, 6780, 10.1073/pnas.97.12.6780
Jin, 2000, Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation, Proc.Natl.Acad.Sci.USA, 97, 6775, 10.1073/pnas.97.12.6775
Friedman, 2002, Ecteinascidin-743 inhibits activated but not constitutive transcription, Cancer Res, 62, 3377
Kanzaki, 2002, Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743, Mol Cancer Ther, 1, 1327
Damia, 2001, Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways, Int J Cancer, 92, 583, 10.1002/ijc.1221
Takebayashi, 2001, Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair, Nat Med, 7, 961, 10.1038/91008
Colombo, 2003, The combination of yondelis and cisplatin is synergistic against human tumor xenografts, Eur J Cancer, 39, 1920, 10.1016/S0959-8049(03)00490-8
Sarries, 2002, Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer, Pharmacogenomics, 3, 763, 10.1517/14622416.3.6.763
Taamma, 2001, Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J Clin Oncol, 19, 1256, 10.1200/JCO.2001.19.5.1256
Ryan, 2001, Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies, Clin Cancer Res, 7, 231
Eckhardt, 2002, A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies, Clin Cancer Res, 8, 75
Twelves, 2003, Phase I and pharmacokinetic study of Yondelis (Ecteinascidin 743; ET-743) administered as an infusion over 1h or 3h every 21 days in patients with solid tumors, Eur J Cancer, 39, 1842, 10.1016/S0959-8049(03)00458-1
Delaloge, 2001, Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity, J Clin Oncol, 19, 1248, 10.1200/JCO.2001.19.5.1248
Demetri, G., Manola, J., Harmon, D., Maki, R., Seiden, R., Supko, J., Ryan, D., Puchlaski, T., Goss, G., Merriam, P., Waxman, A., Slater, S., Potter, A., Quigley, T., Lopez, T., Sancho, MA., Guzman, C., Jimeno, J., and Garcia Carbonero, R. (–, January May). San Francisco, CA. Procc. 352a. Abstract 1406.
Le Cesne, A., Blay, J., Judson, I, Van Oosterom, A, Verweij, J, Radford, J, Lorigan, P, Rodenhuis, S, Donato, De, Paola, E, Van Glabbeke, M., Jimeno, J., and Nielsen, O (–, January May). ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC Phase II trial. San Francisco, CA. Procc. 353a. Abstract 1407.
Yovine, A., Riofrio, M., Brain, E., Blay, JY., Kahatt, C., Delaloge, S., Beautier, L., Cottu, P., Jimeno, J., Cvitkovic, E., and Misset, JL (–, January May). Ecteinascidin-743 given as a 24 hour (H) intravenous continuos infusion (IVCI) every 3 weeks: results of a Phase II trial in patients (PTS) with pretreated soft tissue sarcomas (PSTS). San Francisco, CA. Proc. 363a. Abstract 1449.
Jimeno, J., Maki, R., Casali, P., Faircloth, G., Martinez, N., Nieto, A., and Cañigueral, S Therapeutic impact of ET-743 (Yondelis®, Trabectidin) a new marine derived compound in Sarcoma. Current Opinion in Orthopedics, Submitted September 2003.
Zelek, L., Yovine, A., Brain, E., Jimeno, J., Taamma, A., Martin, C., Spielmann, M., Civtkovic, E., and Misset, JL (2000). Ecteinascidin 743 in pretreated/advanced metastatic breast cancer patients: Preliminary results with the 24 hours infusion schedule. Procc. ASCO New Orleans, 149. abst 592.
Gómez, J., López-Lázaro, L., Guzmán, C., González, A., Misset, J.L., Twelves, C., Bowman, A., Hoekman, K., Villalona, M., Ryan, D., Pazares, L., and Jimeno, J. (2000). Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. ASCO New Orleans, Procc. Abst 727:187ª.
Nieto, 2002, Safety profile of ecteinascidin-743 (ET-743) in phase II clinical trials (CT)in adult patients with solid tumors, Proc Am Soc Clin Oncol, 21, 96a
Colombo, N., Capri, G., Bauer, J., Noberasco, C., De Braud, F., Grasselli, G., Jimeno, J., Ruiz, A., Corradino, I., Marsoni, S., and Sessa, C (, January May). Phase II and Pharmacokinetics study of 3 hour infusion of ET743 in ovarian cancer patients failing platinum-taxanes. Orlando, Florida. Abstract 880.
Casali, P., Casanova, N., Dileo, P., Ferrari, S., Bacci, G., Picci, P., Marsoni, S., Jimeno, J., Riccardi, R., and Gianni, L (3, January May). Activity of Ecteinascidin 743 (ET-trabectedin 743) 3 h infusion in adult and childhood small round cell sarcomas. Chicago IL. Proc Vol. 22 Abs. 962.
Forouzesh, B., Hidalgo, M., Denis, L., Schwart, G., Hammond, L., Monroe, P., Guzman, C., Lopez-Lazaro, L., Supko, J., Jimeno, J., and Rowinsky, E. (2, January October). phase I and pharmacokinetic study of the marinederived DNA minor groove binder ET-743 on a weekly x3 every-4-week schedule in patients with advanced solid malignancies. Miami Beach.
Grasselli, 2003, Phase I and pharmacokinetic (PK) study of ecteinascidin-743 (ET, Trabectedin) and cisplatin (P) combination in pre-treated patients (pts) with selected advanced solid tumors, Proc Am Soc Clin Oncol, 22, 542
Rinehart, 1981, Structures of the Didemnins, Antiviral and Cytotoxic Depsipeptides from a Caribbean Tunicate, J Am Chem Soc, 103, 1857, 10.1021/ja00397a055
Erba, 2002, Cell Cycle phase perturbations and apoptosis in tumour cells induced by aplidine, Br J Cancer, 86, 1510, 10.1038/sj.bjc.6600265
Broggini, 2003, Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4, Leukemia, 17, 52, 10.1038/sj.leu.2402788
Anthoney, A., Paz-Ares, L., Twelves, C., Cortes-Funes, H., Kaye, S., Pronk, L., Celli, N., Lopez-Lazaro, L., Guzman, C., and Jimeno, J (2000). Phase I and Pharmacokinetic (PK) Study of APL (APL) Using a 24-Hour, Weekly Schedule. Proc Am Soc Clin Oncol, abstract #734.
Ciruelos, E.M., Twelves, C., Dominguez, M.J., Mckay, H., Anthony, A, Castellanos, D., Bezares, S., Ruiz, A., Lopez-Lazaro, L., Jimeno, J., Celli, C., Cortes-Funes, H., and Paz-Ares, L (2002). Phase I clinical and pharmacokinetic study of the marine compound APL (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol, abstract # 422.
Bowman, A., Izquierdo, M.A., Jodrell, D., Martinez, M., Cicchella, B., Jimeno, J., Guzman, C., Germa-Lluch, J., Celli, N., and Smyth, J (2001). Phase I Clinical and Pharmacokinetic (PK) Study of the Marine Compound APL (APL), administered as a 1 Hour Weekly Infusion. Proc Am Soc Clin Oncol, abstract #476.
Armand, J.P., Ady-Vago, N., Faivre, S., Chieze, S., Baudin, E., Ribrag, V., Lecot, F., Iglesias, L., López-Lázaro, L., Guzmán, C., Jimeno, J., Ducreux, M., Le Chevalier, T., and Raymond, E (2001). Phase I and Pharmacokinetic Study of APL Given as a 24-Hour Continuous Infusion Every Other Week (q2w) in Patients (pts) with Solid Tumor (ST) and Lymphoma (NHL). Proc Am Soc Clin Oncol, abstract #477.
Maroun, J.A., Goel, R., Stewart, D.J., Tomiak, E., Belanger, K., Soulieres, D., Charpentier, D., Seymour, L., Matthews, S., Jimeno, J., and Guzman, C (2001). Phase I Study of APL in a 5 Day Bolus Q 3 Weeks in Patients with Solid Tumors and Lymphomas. Proc Am Soc Clin Oncol, abstract #2082.
Bresters, D., Broekhuizen, A., Faircloth, G., Jimeno, J., and Kaspers, G (2003). In vitro cytotoxicity of Aplidine and cross-resistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples; a rational basis for clinical development. Leukemia, 1–6.
Erba, 2003, The effect of Aplidine in acute lymphoblastic leukaemia cells, Br J Cancer Suppl, 89, 763, 10.1038/sj.bjc.6601130
Raymond, 2002, Activity of APL, a new marine compound, against medullary thyroid carcinoma (MTC): Phase I trials as screening tools for rare tumors, Ann Oncol., 13, 22
Hamann, 1996, Kahalalides: Bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp, J. Org. Chem, 61, 6594, 10.1021/jo960877+
Hamann, 1993, Kahalalide F: A bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp, J Am Chem Soc, 115, 5825, 10.1021/ja00066a061
Bonay, 1996, The antitumor compound Kahalalide F acts on cell lysosomes, Cancer Lett, 99, 43, 10.1016/0304-3835(95)04036-6
Suarez, Y., Gonzalez, L., Cuadrado, A., Berciano, M., Lafarga, M., and Muñoz, A (2003). Kahalalide F, a new marine derived compound induces oncosis in human prostate and breast cancer cells. Mol. Cancer Therapeutics, 863–872.
Supko, J.G, Lu, H., Jimeno, J.M., Grant, W., and Faircloth, G.T. (, January November). Preclinical pharmacology studies with the marine natural product Kahalalide F. Washington D.C.. Abstract no. 315.
Ciruelos, 2002, A phase I clinical and pharmacokinetic (PK) study with KahalalideF (KF) in patients (pts) with advanced solid tumours (AST) with a continuous weekly (W) 1-hour iv infusion schedule, European Journal of Cancer, 38, S33, 10.1016/S0959-8049(02)80744-4
Schellens, J.H.M., Rademakerlakhai, J.M., Horenblas, S., Meinhardt, W., Stokvis, E., De Reijke, T.M., Jimeno, J., Lopez-Lazaro, L., Lopez-Martin, J.A., and Beijnen, J.H. (2002, January May). Phase I and pharmacokinetic study of kahalalide F in patients with advanced androgen resistant prostate cancer. Orlando, Florida. Proc.113a, Vol., 21, Abstract 451.
Cuevas, 2000, Síntesis of Ecteinascidin ET-743 and phthalascidin PT-650 from syano safracin B, Org. Lett, 2, 2245, 10.1021/ol0062502
Joug, 1997, Total síntesis of dehydro didemnin B. Use of uranium and phosphonium salt coupling reagents in peptide synthesis in solution, J. Org. Chem, 62, 354, 10.1021/jo961932h
Royo, 2001, Synthesis and structure determination of Kahalalide F, Am. Chem Society, 123, 11398, 10.1021/ja0116728
Cuadros, 2000, The marine compound Spisulosine, and inhibitor of cell proliferation promotes the disassembly of actin stress fibers, Cancer Lett, 152, 23, 10.1016/S0304-3835(99)00428-0
Jimeno, J., García-Grávalos, D., Ávila, J., Smith, B., Grant, W., and Faircloth, G.T. (1999, January November). ES-285, a marine natural product with activity against solid tumors. Washington, D.C.. Abstract no. 314.
Sanchez Beato, M., Moneo, V, Martínez, N, Fernández, I, Carnero, A, Piris, MA, and Jimeno, J (2003, January October). Molecular pharmacodynamic (MPD) effects induced by ET-743 (Yondelis) in human sarcoma cells (HSC). Amsterdam, The Netherlands. Abstract C-1465.